Dr. James Galloway

Professional qualifications

MB ChB University of Bristol (2001)
MRCP Royal College of Physicians London (2005)
MSc Clinical Rheumatology University of Manchester (2008)
PhD University of Manchester (2012)
CCT in rheumatology JRCPTB (2012)

Membership of professional bodies
• American College of Rheumatology
• British Medical Association
• British Rheumatology Society
• Royal College of Physicians
Current post

Lecturer and honorary consultant rheumatologist King’s College London May 2012 – present

My primary contract is with King’s College London University. My position is split 50:50 between clinical rheumatology and research. My current research commitments are with the King’s UKCRC accredited clinical trials unit. My clinical commitments are involved primarily with managing rheumatoid arthritis, including running the biologics assessment service

Teaching experience

• Undergraduate lead for rheumatology at King’s College Hospital
• Lecturer for range of Masters programmes at King’s College London (Immunology, Translational Medicine, Physiotherapy, Pharmacology)

• Pastest consultant
MRCP part 1, part 2 and PACES teacher
Development of written materials, online content, lectures and clinical skills training

• Independent MRCP part 1 course
Established 2006, now with an established reputation in the UK

Research experience

• PhD in clinical epidemiology
Title: Studying the risk of infections with biologic agents

I have completed a PhD in clinical epidemiology. During three years in full time research I presented my work at both national and international meetings as well as publishing my findings in high standing peer reviewed journals.

Research awards

2010 BSR Young Investigators Award, BSR Annual Conference
2009 Lenox Holt Prize, North West Rheumatology Research Afternoon
2009 Best Poster, University of Manchester Postgraduate Research Day

Publications

Peer reviewed original publications
(1-10)
1. Zavada J, Lunt M, Davies R, Low AS, Mercer LK, Galloway JB, et al. The risk of gastrointestinal perforations in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the BSRBR-RA. Annals of the rheumatic diseases. 2013 May 5. PubMed PMID: 23644671.
2. Viatte S, Plant D, Lunt M, Fu B, Flynn E, Parker BJ, et al. Investigation of rheumatoid arthritis genetic susceptibility markers in the early rheumatoid arthritis study further replicates the TRAF1 association with radiological damage. The Journal of rheumatology. 2013 Feb;40(2):144-56. PubMed PMID: 23242182.
3. Mercer LK, Low AS, Galloway JB, Watson KD, Lunt M, Symmons DP, et al. Anti-TNF therapy in women with rheumatoid arthritis with a history of carcinoma in situ of the cervix. Annals of the rheumatic diseases. 2013 Jan;72(1):143-4. PubMed PMID: 22843488.
4. Mercer LK, Davies R, Galloway JB, Low A, Lunt M, Dixon WG, et al. Risk of cancer in patients receiving non-biologic disease-modifying therapy for rheumatoid arthritis compared with the UK general population. Rheumatology (Oxford). 2013 Jan;52(1):91-8. PubMed PMID: 23238979. Pubmed Central PMCID: 3521445.
5. Galloway JB, Mercer LK, Moseley A, Dixon WG, Ustianowski AP, Helbert M, et al. Risk of skin and soft tissue infections (including shingles) in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Annals of the rheumatic diseases. 2013 Feb;72(2):229-34. PubMed PMID: 22532633. Pubmed Central PMCID: 3595979.
6. Fu B, Lunt M, Galloway J, Dixon W, Hyrich K, Symmons D. A threshold hazard model for estimating serious infection risk following anti-tumor necrosis factor therapy in rheumatoid arthritis patients. Journal of biopharmaceutical statistics. 2013 Mar 11;23(2):461-76. PubMed PMID: 23437951.
7. Galloway JB, Hyrich KL, Mercer LK, Dixon WG, Watson KD, Lunt M, et al. The risk of serious infections in patients receiving anakinra for rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Rheumatology (Oxford). 2011 Jul;50(7):1341-2. PubMed PMID: 21489973.
8. Galloway JB, Hyrich KL, Mercer LK, Dixon WG, Ustianowski AP, Helbert M, et al. Risk of septic arthritis in patients with rheumatoid arthritis and the effect of anti-TNF therapy: results from the British Society for Rheumatology Biologics Register. Annals of the rheumatic diseases. 2011 Oct;70(10):1810-4. PubMed PMID: 21784730. Pubmed Central PMCID: 3168332.
9. Galloway JB, Hyrich KL, Mercer LK, Dixon WG, Fu B, Ustianowski AP, et al. Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly. Rheumatology (Oxford). 2011 Jan;50(1):124-31. PubMed PMID: 20675706. Pubmed Central PMCID: 3105607.
10. Dixon WG, Hyrich KL, Watson KD, Lunt M, Galloway J, Ustianowski A, et al. Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: Results from the British Society for Rheumatology Biologics Register (BSRBR). Annals of the rheumatic diseases. 2009 Oct 22. PubMed PMID: 19854715. Epub 2009/10/27. Eng.

2 responses on "Dr. James Galloway"

  1. Concise, Precise, Perfect and Interesting!!! Brilliant oration with great command on the subject. Doesn’t need my approval for above comments but it is my humble attempt to show my appreciation as I have just cleared PLAB Part 1 without guidance and I totally appreciate the help I got, especially in India. Thank you sir!!!

  2. I am appearing for September 2017 SCE in Rheumalogy.can you please suggest a coaching course on line
    Thanks

Leave a Message

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

top
© 2018 All Rights Reserved. Registration No: 08799952 (Reg. in England & Wales) - Register Office : 23 Hanover Square, Mayfair, London W1S 1JB
X